The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients

Acta Obstetricia et Gynecologica Scandinavica

Volumn 79, Issue 7, 2000, Pages 604-607

  Kavak, Zehra Neşe ^a,b   Binöz, Sedef ^a   Ceyhan, Nejat ^a   Pekin, Sakip ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast cancer; Endometrium; Tamoxifen

Indexed keywords

FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; LIPID; LUTEINIZING HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; CURETTAGE; DRUG EFFICACY; ENDOMETRIUM; ENDOMETRIUM CYTOLOGY; FOLLITROPIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIPIDS; MASS SCREENING; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 0033918618     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2000.079007604.x     Document Type: Article

References (15)

1. 1. Cohen I, Rosen DJ, Shapiro J, Cordoba M, Gilboa S, Altaras M et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993; 100: 567-9.
2. 2. Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol 1996; 174: 141-4.
3. 3. Neven P, Shepherd JH, Lowe DG. Tamoxifen and gynecologist. Br J Obstet Gynaecol 1993; 100: 893-7.
4. 4. Timmerman D, Deprest J, Bourne T, Berghe I, Collins WP, Vergote I. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 1998; 179: 62-70.
5. 5. Timor Tritsch IE, Rottem S, Boldo R. Scanning the uterus. In: Timor Tritsch IE, Rottem S, eds. Transvaginal Sonograpy. New York: Elsevier, 1988; 27-43.
6. 6. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer and thromboembolic episodes. J Clin Oncol 1998; 16: 2018-24.
7. 7. Ziel HK. Estrogen's role in endometrial cancer. Obstet Gynecol 1982; 60: 509-15.
8. 8. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-90.
9. 9. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrave D et al. Effect of tamoxifen on uterus and ovaries of postmenapausal women in randomised breast cancer prevention trial. Lancet 1994; 343: 1318-21.
10. 10. Bertelli G, Venturini M, Del Mastro L, Garrane O, Cassa M, Gustavino C et al. Tamoxifen and the endometrium : findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998; 47: 41-6.
11. 11. Lahti E, Blanco G, Kauppila A, Sakkinen A, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receving tamoxifen. Obstet Gynecol 1993; 81: 660-4.
12. 12. Neven P, Muylder XD, Belle YV, Haag I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 1998; 351: 175.
13. 13. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions. Lancet 1998; 351: 155-6.
14. 14. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991; 303; 435-6.
15. 15. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RAB. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 1992; 305: 225-6.